Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Sevion Therapeutics Inc.
DescriptionIon channel blocking antibody targeting Kv1.3
Molecular Target Potassium channel Kv1.3 (KCNA3)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Autoimmune (unspecified)
Indication DetailsTreat autoimmune disorders
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today